Novel Artificial Erythrocyte for In-Field Resuscitation of Hemorrhagic Shock
Abstract
The first ErythroMer prototype (EM-V1) was structurally stable and toroidal, with diameter ~ 1/50th that of RBCs and amenable to lyophilization and rapid reconstitution. In addition, EM p50 (with novel pseudo-Bohr effect), NO sequestration and vasoactivity were equivalent to RBCs establishing POC for the bio-inspired design. In our novel rabbit hemorrhagic shock model, for both hemodynamic and O2 delivery outcomes, EMV1 was non-inferior to shed blood and superior to 5% Albumin. To further optimize biocompatibility, circulation time, and Hb payload density/retention, we developed EM-V2. In prior reports, we included data on V2 benchtop characterization, which recapitulates RBC physiology similarly to V1. Of note, just prior to the end of project Y2, Dr. Doctor was recruited from Washington University (WUSM) to the University of Maryland (UMB), to serve as founding director for the Center for Blood Oxygen Transport and Hemostasis (CBOTH). Our PFCRA team was reorganized and KaloCyte relocated from St Louis to Baltimore. Resulting from these changes, the timing of contract transition from WUSM to UMB, and from COVID19 related lab shutdowns, the only project work in Y3 was performed by KaloCyte. As such, two sequential NCEs have been approved. CBOTH reopened in Y4 at 25% capacity, by Q4 we were fully operational; during that period, we completed biocompatibility, rheology, PK/biodistribution/elimination experiments and advanced modeling of PFC dosing requirements; we re-established our HS/R model (with new O2 delivery-consumption analyses), confirming EM V2 efficacy and initiated pilot work for our PFCRA survival model.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2023
- Accession Number
- AD1216825
Entities
People
- Allan Doctor
Organizations
- University of Maryland, Baltimore